UK flag Brexit: What We Are (And Aren't) Doing Get the Fool's analysis on what the UK leaving the EU means for investors

Rexahn Pharmaceuticals Inc. is a clinical stage biopharmaceutical company developing and seeking to deliver novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide.


Updates from The Motley Fool

Latest updates on Rexahn Pharmaceuticals from Fool.com.


Stock Performance

RNN vs. S&P 500 | 2 Year Performance
View Interactive RNN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Rexahn Pharmaceuticals.
Current Price: $0.25
Prev Close: $0.26
Open: $0.26
Bid: $0.23
Ask: $0.31
Day's Range: $0.24 - $0.26
52wk Range: $0.24 - $0.71
Volume: 1,573,480
Avg Vol 765,216
Market Cap: $44.95M
P/E (ttm): -3.25
EPS (ttm): -$0.08
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Rexahn Pharmaceuticals.
CAPS Rating 3 out of 5
 
87 Outperform
14 Underperform
CAPS All Stars
 
7 Outperform
6 Underperform

How do you think Rexahn Pharmaceuticals will perform against the market?



You pick for Rexahn Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


Business Summary

Industry, sector and description for Rexahn Pharmaceuticals.

Rexahn Pharmaceuticals Inc. is a clinical stage biopharmaceutical company developing and seeking to deliver novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide.

  • Exchange: NYSEMKT
  • Sector: Healthcare
  • Industry: Drug Makers